WINTON GROUP Ltd Invests $1.08 Million in Inspire Medical Systems, Inc. (NYSE:INSP)

WINTON GROUP Ltd bought a new stake in Inspire Medical Systems, Inc. (NYSE:INSP) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 8,097 shares of the company’s stock, valued at approximately $1,084,000.

A number of other large investors have also added to or reduced their stakes in INSP. SouthState Corp bought a new position in shares of Inspire Medical Systems during the 2nd quarter valued at about $27,000. Daiwa Securities Group Inc. bought a new position in Inspire Medical Systems during the second quarter valued at approximately $53,000. Principal Securities Inc. purchased a new position in shares of Inspire Medical Systems during the fourth quarter worth approximately $54,000. Van ECK Associates Corp lifted its holdings in shares of Inspire Medical Systems by 7.5% in the 2nd quarter. Van ECK Associates Corp now owns 1,029 shares of the company’s stock worth $138,000 after acquiring an additional 72 shares during the last quarter. Finally, RiverPark Advisors LLC boosted its stake in shares of Inspire Medical Systems by 360.1% in the 1st quarter. RiverPark Advisors LLC now owns 773 shares of the company’s stock valued at $166,000 after purchasing an additional 605 shares in the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on INSP shares. Bank of America cut their price target on shares of Inspire Medical Systems from $225.00 to $185.00 and set a “neutral” rating for the company in a research report on Monday, June 3rd. Morgan Stanley reduced their price target on Inspire Medical Systems from $250.00 to $210.00 and set an “overweight” rating on the stock in a research report on Monday, July 15th. KeyCorp lowered their price objective on Inspire Medical Systems from $278.00 to $236.00 and set an “overweight” rating for the company in a research report on Wednesday, August 7th. Robert W. Baird cut their target price on shares of Inspire Medical Systems from $220.00 to $200.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Finally, Truist Financial lowered their price target on shares of Inspire Medical Systems from $280.00 to $217.00 and set a “buy” rating for the company in a report on Tuesday, July 16th. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Inspire Medical Systems presently has an average rating of “Moderate Buy” and an average target price of $214.85.

Insider Activity at Inspire Medical Systems

In other Inspire Medical Systems news, insider Randy Ban sold 4,861 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $188.55, for a total transaction of $916,541.55. Following the completion of the transaction, the insider now owns 3,056 shares of the company’s stock, valued at $576,208.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Inspire Medical Systems news, insider Randy Ban sold 4,861 shares of the business’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $188.55, for a total value of $916,541.55. Following the sale, the insider now directly owns 3,056 shares of the company’s stock, valued at $576,208.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Shawn Mccormick sold 800 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $220.00, for a total value of $176,000.00. Following the transaction, the director now owns 23,140 shares of the company’s stock, valued at $5,090,800. The disclosure for this sale can be found here. Insiders sold a total of 5,692 shares of company stock valued at $1,099,207 in the last three months. Company insiders own 4.10% of the company’s stock.

Inspire Medical Systems Price Performance

INSP stock opened at $203.99 on Monday. The firm has a 50-day moving average of $168.99 and a 200 day moving average of $181.09. The company has a market cap of $6.08 billion, a P/E ratio of -370.89 and a beta of 1.33. Inspire Medical Systems, Inc. has a 1 year low of $123.00 and a 1 year high of $257.40.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.46. The company had revenue of $195.89 million during the quarter, compared to analysts’ expectations of $189.08 million. Inspire Medical Systems had a return on equity of 1.03% and a net margin of 0.85%. The firm’s revenue for the quarter was up 29.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.41) EPS. On average, equities research analysts expect that Inspire Medical Systems, Inc. will post 0.75 earnings per share for the current fiscal year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.